Source - SMW
Spectris said it had completed the acquisition of drug development group Concept Life Sciences from Equistone Partners Europe and company management for £163m.

The deal would be funded from existing cash and bank facilities, the company said.

Concept's pro-forma revenue in the year through December was £48.7m and pro-forma Ebitda was £9.3m.

"The business has a history of delivering double-digit growth and we expect that to continue," Spectris said.




Related Charts

Spectris (SXS)

-24.00p (-0.87%)
delayed 17:30PM